References:
References:
1. Borgström, L.; Kågedal, B.; Paulsen, O. (1986). "Pharmacokinetics of N-acetylcysteine in man". European Journal of Clinical Pharmacology 31 (2): 217–222. doi:10.1007/BF00606662. PMID 3803419.
2. Dilger, R. N.; Baker, D. H. (2007). "Oral N-acetyl-L-cysteine is a safe and effective precursor of cysteine". Journal of Animal Science 85 (7): 1712–8. doi:10.2527/jas.2006-835. PMID 17371789.
3. Kanter, M. Z. (2006). "Comparison of oral and i.v. Acetylcysteine in the treatment of acetaminophen poisoning". American Journal of Health-System Pharmacy 63 (19): 1821–7. doi:10.2146/ajhp060050. PMID 16990628.
4. Dawson, AH; Henry, DA; McEwen, J (1989). "Adverse reactions to N-acetylcysteine during treatment for paracetamol poisoning". The Medical journal of Australia 150 (6): 329–31. PMID 2716644.
5. Bailey, B; McGuigan, M (1998). "Management of Anaphylactoid Reactions to Intravenous -Acetylcysteine". Annals of Emergency Medicine 31 (6): 710–5. doi:10.1016/S0196-0644(98)70229-X. PMID 9624310.
6. Schmidt, L. E.; Dalhoff, K (2008). "Risk factors in the development of adverse reactions to N-acetylcysteine in patients with paracetamol poisoning". British Journal of Clinical Pharmacology 51 (1): 87–91. doi:10.1046/j.1365-2125.2001.01305.x. PMC 2014432. PMID 11167669.
7. Lynch, R; Robertson, R (2004). "Anaphylactoid reactions to intravenous N-acetylcysteine: a prospective case controlled study". Accident and Emergency Nursing 12 (1): 10–5. doi:10.1016/j.aaen.2003.07.001. PMID 14700565
8. Tepel, Martin; Van Der Giet, Marcus; Schwarzfeld, Carola; Laufer, Ulf; Liermann, Dieter; Zidek, Walter (2000). "Prevention of Radiographic-Contrast-Agent–Induced Reductions in Renal Function by Acetylcysteine". New England Journal of Medicine 343 (3): 180–4. doi:10.1056/NEJM200007203430304. PMID 10900277.
9. Hoffmann, U.; Fischereder, M; Krüger, B; Drobnik, W; Krämer, BK (2004). "The Value of N-Acetylcysteine in the Prevention of Radiocontrast Agent-Induced Nephropathy Seems Questionable". Journal of the American Society of Nephrology 15 (2): 407–10. doi:10.1097/01.ASN.0000106780.14856.55. PMID 14747387.
10. Miner, S; Dzavik, V; Nguyen-Ho, P; Richardson, R; Mitchell, J; Atchison, D; Seidelin, P; Daly, P; Ross, J et al. (2004). "N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up". American Heart Journal 148 (4): 690–5. doi:10.1016/j.ahj.2004.05.015. PMID 15459602.
11. Marenzi, Giancarlo; Assanelli, Emilio; Marana, Ivana; Lauri, Gianfranco; Campodonico, Jeness; Grazi, Marco; De Metrio, Monica; Galli, Stefano; Fabbiocchi, Franco et al. (2006). "N-Acetylcysteine and Contrast-Induced Nephropathy in Primary Angioplasty". New England Journal of Medicine 354 (26): 2773–82. doi:10.1056/NEJMoa054209. PMID 16807414.
12. Kay, J.; Chow, WH; Chan, TM; Lo, SK; Kwok, OH; Yip, A; Fan, K; Lee, CH; Lam, WF (2003). "Acetylcysteine for Prevention of Acute Deterioration of Renal Function Following Elective Coronary Angiography and Intervention: A Randomized Controlled Trial". JAMA 289 (5): 553–8. doi:10.1001/jama.289.5.553. PMID 12578487.
13. Act, Investigators (September 2011). "Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT)". Circulation 124 (11): 1250–9.
14. Szilárd, S; Szentgyörgyi, D; Demeter, I (1988). "Protective effect of Legalon in workers exposed to organic solvents". Acta medica Hungarica 45 (2): 249–56. PMID 3073356.
15. Palasciano, Giuseppe; Portincasa, Piero; Palmieri, Vincenzo; Ciani, Daniela; Vendemiale, Gianluigi; Altomare, Emanuele (1994). "The effect of silymarin on plasma levels of malon-dialdehyde in patients receiving long-term treatment with psychotropic drugs". Current Therapeutic Research 55 (5): 537–45. doi:10.1016/S0011-393X(05)80184-5.
16. Angulo, P; Patel, T; Jorgensen, RA; Therneau, TM; Lindor, KD (2000). "Silymarin in the Treatment of Patients with Primary Biliary Cirrhosis with a Suboptimal Response to Ursodeoxycholic Acid". Hepatology 32 (5): 897–900. doi:10.1053/jhep.2000.18663. PMID 11050036.
17. Lieber, Charles S.; Leo, Maria A.; Cao, Qi; Ren, Chaoling; Decarli, Leonore M. (2003). "Silymarin Retards the Progression of Alcohol-Induced Hepatic Fibrosis in Baboons". Journal of Clinical Gastroenterology 37 (4): 336–9. doi:10.1097/00004836-200310000-00013. PMID 14506392.
18. Ladas, Elena J.; Kroll, David J.; Oberlies, Nicholas H.; Cheng, Bin; Ndao, Deborah H.; Rheingold, Susan R.; Kelly, Kara M. (2010). "A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL)". Cancer 116 (2): 506–13. doi:10.1002/cncr.24723. PMC 3542639. PMID 20014183.
19. Naruta, E.; Buko, V. (2001). "Hypolipidemic effect of pantothenic acid derivatives in mice with hypothalamic obesity induced by aurothioglucose". Experimental and Toxologic Pathology 53 (5): 393–398. doi:10.1078/0940-2993-00205. PMID 11817109.
20. Harry Fong & Jerry Bauman 2002. Alternative Medicines for Cardiovascular Diseases--Hawthorn, Journal of Cardiovascular Nursing 16(4):1-8.
21. Sweet JMRBV (2002). Hawthorn: Pharmacology and therapeutic uses. American Journal of Health-System Pharmacy 59: 417-422.
22. Miodownik C, Lerner V, Vishne T, et al. High-dose vitamin B6 decreases homocysteine serum levels in patients with schizophrenia and schizoaffective disorders: a preliminary study. Clin Neuropharmacol 2007 Jan-Feb;30(1):13-7.
23. Schnyder G, Roffi M, Flammer Y, et al. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. JAMA 8-28-2002;288(8):973-979.
24. Markowitz JS, Donovan JL, Devane CL, et al. (December 2003). "Multiple doses of saw palmetto (Serenoa repens) did not alter cytochrome P450 2D6 and 3A4 activity in normal volunteers". Clin. Pharmacol. Ther. 74 (6): 536–42. doi:10.1016/j.clpt.2003.08.010. PMID 14663456.
25. Wilt T, Ishani A, Mac Donald R (2002). "Serenoa repens for benign prostatic hyperplasia". In Tacklind, James. Cochrane Database Syst Rev (3): CD001423. doi:10.1002/14651858.CD001423. PMID 12137626.
26. Bent S, Kane C, Shinohara K, et al. (February 2006). "Saw palmetto for benign prostatic hyperplasia". N. Engl. J. Med. 354 (6): 557–66. doi:10.1056/NEJMoa053085. PMID 16467543.
27. Dedhia RC, McVary KT (June 2008). "Phytotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia". J. Urol. 179 (6): 2119–25.
28. "Saw Palmetto". MedlinePlus (National Library of Medicine). 2008-02-01.
29. Sultana, S., Ahmed, S., Jahangir, T., & Sharma, S. (2005). Inhibitory effect of celery seeds extract on chemically induced hepatocarcinogenesis: modulation of cell proliferation, metabolism and altered hepatic foci development. Cancer letters, 221(1), 11-20.
30. Le QT, Elliott WJ. Hypotensive and hypocholesterolemic effects of celery oil may be due to BuPh. Clin Res. 1991;39:173A.
31. Bagchi, Debasis; Sen, Chandan K; Ray, Sidhartha D; Das, Dipak K; Bagchi, Manashi; Preuss, Harry G; Vinson, Joe A (2003). "Molecular mechanisms of cardioprotection by a novel grape seed proanthocyanidin extract". Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis. 523-524: 87–97. doi:10.1016/S0027-5107(02)00324-X. PMID 12628506
32. Vitseva, Olga; Varghese, Sonia; Chakrabarti, Subrata; Folts, John D; Freedman, Jane E (2005). "Grape Seed and Skin Extracts Inhibit Platelet Function and Release of Reactive Oxygen Intermediates". Journal of Cardiovascular Pharmacology 46 (4): 445–51.
33. Pan, Xinjuan; Dai, Yujie; Li, Xing; Niu, Nannan; Li, Wenjie; Liu, Fangli; Zhao, Yang; Yu, Zengli (2011). "Inhibition of arsenic induced-rat liver injury by grape seed exact through suppression of NADPH oxidase and TGF-β/Smad activation". Toxicology and Applied Pharmacology 254 (3): 323–31. doi:10.1016/j.taap.2011.04.022. PMID 21605584.
34. Liu, S.; Tan, M. Y.; Zhao, S. P.; Rong, H. (2012). "Effects of policosanol on serum lipids and heme oxygenase-1 in patients with hyperlipidemia". Zhonghua xin xue guan bing za zhi 40 (10): 840–843. PMID 23302671. edit
35. Zanardi, M.; Quirico, E.; Benvenuti, C.; Pezzana, A. (2012). "Use of a lipid-lowering food supplement in patients on hormone therapy following breast cancer". Minerva ginecologica 64 (5): 431–435. PMID 23018482.
36. Blando, F., Gerardi, C., & Nicoletti, I. (2004). Sour Cherry (Prunus cerasus L) Anthocyanins as Ingredients for Functional Foods. Journal of Biomedicine and Biotechnology, 2004(5), 253-258. Hindawi Publishing Corporation.
37. Higashiyama, K.; Takeuchi, Y.; Yamauchi, T.; Imai, S.; Kamei, J.; Yajima, Y.; Narita, M.; Suzuki, T. (May 2005). "Implication of the Descending Dynorphinergic Neuron Projecting to the Spinal Cord in the (+)-Matrine- and (+)-Allomatrine-Induced Antinociceptive Effects" (pdf). Biological and Pharmaceutical Bulletin 28 (5): 845–848. doi:10.1248/bpb.28.845. PMID 15863891.
38. Ma, L.; Wen, S.; Zhan, Y.; He, Y.; Liu, X.; Jiang, J. (2008). "Anticancer Effects of the Chinese Medicine Matrine on Murine Hepatocellular Carcinoma Cells". Planta Medica 74 (3): 245–251. doi:10.1055/s-2008-1034304. PMID 18283616.
39. Wenzel, E., & Somoza, V. (2005). Metabolism and bioavailability of trans-resveratrol. Molecular nutrition & food research, 49(5), 472-481.
40. Xue, L. X. (1993). Experimental study on extract of Dunaliella salina in preventing NSAR-induced cancer of proventriculus in mice. Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine], 27(6), 350-353.
41. Herrero, M., Ibáñez, E., Cifuentes, A., Reglero, G., & Santoyo, S. (2006). Dunaliella salina microalga pressurized liquid extracts as potential antimicrobials. Journal of food protection, 69(10), 2471-2477.